Clinical Trials
21 trialsNCT03526250 2026-04-03
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Completed
NCT03233204 2024-12-11
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Completed
NCT00019630 2024-03-04
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00020150 2015-04-29
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT01088763 2014-11-05
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00002647 2013-09-20
Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00349024 2013-09-20
Polyvinylpyrrolidone-Sodium Hyaluronate Gel in Reducing Pain From Oral Mucositis in Young Patients With Cancer
National Cancer Institute (NCI)
Phase NA Unknown
NCT00002608 2013-07-10
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00012181 2013-07-02
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Phase 1 Completed
NCT00994500 2013-07-02
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00513981 2013-06-26
High-Dose Methotrexate in Treating Young Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00077454 2013-06-05
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00091182 2013-06-05
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
National Cancer Institute (NCI)
Phase 2 Completed
NCT00101270 2013-06-05
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Phase 1 Completed
NCT00002825 2013-02-05
Docetaxel in Treating Children With Recurrent Solid Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00006102 2013-02-05
Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00008008 2013-02-04
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00363272 2013-01-16
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00030108 2012-03-15
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00036959 2012-03-15
ABT-751 in Treating Young Patients With Refractory Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00303940 2012-03-15
Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed